Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.
about
Do oxysterols control cholesterol homeostasis?Lipid biomarkers of oxidative stress in a genetic mouse model of Smith-Lemli-Opitz syndrome7-Dehydrocholesterol-derived oxysterols and retinal degeneration in a rat model of Smith-Lemli-Opitz syndromeAnalysis of oxysterols by electrospray tandem mass spectrometry.Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.Inhibition of human cytochrome P450 3A4 by cholesterolQuantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS.Novel oxysterols observed in tissues and fluids of AY9944-treated rats: a model for Smith-Lemli-Opitz syndrome.No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation.Systematic review: ursodeoxycholic acid--adverse effects and drug interactions.4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.miRNA-27b levels are associated with CYP3A activity in vitro and in vivo.Metabolism of oxysterols derived from nonenzymatic oxidation of 7-dehydrocholesterol in cells.Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy.4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?Cytochrome P450--physiological key factor against cholesterol accumulation and the atherosclerotic vascular process.A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 inductionKnockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver.Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.The effect of oral lipids and circulating lipoproteins on the metabolism of drugs.Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease.Conversion of 7-dehydrocholesterol to 7-ketocholesterol is catalyzed by human cytochrome P450 7A1 and occurs by direct oxidation without an epoxide intermediate.Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism.Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.Cholesterol 25-hydroxylation activity of CYP3A.An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects.Metabolism of 4 beta -hydroxycholesterol in humans.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model.The Influence of an Obesogenic Diet on Oxysterol Metabolism in C57BL/6J Mice.Still another activity by the highly promiscuous enzyme CYP3A4: 25-hydroxylation of cholesterol.
P2860
Q24553299-F1841883-08E5-486E-B937-03B6315750C3Q24615855-015C4D88-39B8-451A-A31A-1D1FAAE3712BQ24631190-D9AA0CA0-96BC-4362-AE77-DE6D0AA53A8AQ33434723-5723B3C8-5D3E-422F-B431-BA4DFA0711D1Q33870649-0B530CDF-72C3-4DBC-9FF9-0457FC90EF0BQ34570949-494E55E8-7FD9-4990-8595-DFDAEE85FEABQ34580565-72B30A82-2E42-4181-80F6-D497322FB02BQ34998005-F8C9AD5C-95A1-49AA-ABA9-DA277520E0A3Q35174116-37A17B8D-75E8-4D00-B98B-2969EB1BDE9EQ35212891-D956D3A7-03CC-420A-8110-AE24FBDD3AA7Q35249663-4CB583DD-E1B9-4AC0-8CD2-55676AB98FC5Q35583064-623896D6-4389-486A-95B2-59CF4D1D92F5Q36072512-60C6D0B5-6D62-48EB-BB6B-0AEBF9BE6B83Q36410123-DF84B2AF-1E85-45AA-8DD2-746908730EADQ36495172-709A2C85-AF46-47B3-8C7C-9DAFAAB3FDB0Q36618692-F57DCDCF-4919-468F-9873-6BC4695D4AB5Q36648836-37E909A2-4CE9-4E27-9C15-DB97EE9E14B6Q36709608-96B882DB-4896-4AE3-BC98-99DC210DD117Q36729155-89A629EB-9CB5-4A5F-B0C3-71CA0B3C1239Q36802040-DD758CAB-247C-4953-B11A-8797A4BE2683Q36911423-CCBE5466-5275-41DB-9F12-1283648243A5Q36948140-31733E50-2B8B-48FB-BB40-95852A500BEBQ37002627-20B403D5-19E1-4860-81C9-091B1351900CQ37076544-CAED23BA-9BDF-492E-A240-C4D0690D428BQ37575518-47D1B1EF-0B98-44A8-AC34-A8C72A46A438Q37579733-509FC8B1-4631-4A5F-B74E-09C04BC609FBQ37700667-32E7DB41-BFE4-4FBE-8D44-560C16A76D6DQ38133807-D44A989E-6C41-4D1D-839D-54EF50E30969Q38675000-9CF4F7EE-11BC-4FC4-A197-B6AD27138C11Q38813488-87EB8AE1-5021-42C4-9773-1834684F4511Q38986439-59368B05-1351-4023-A721-98D16DBC2147Q39062220-15FFADB4-36E7-4A97-AA99-C51E9341D3FFQ39253133-CC69BE5F-A906-4BFE-95DC-4E798D80D575Q39541370-559C8B3A-CCED-41BF-990C-3FD9E5AEEDE8Q39800984-C12EB7AF-5EC1-44B8-9FDF-2E5A4329C454Q40723392-8C7E3628-EBA6-492E-A884-30FCEFCE0363Q41328717-B916E870-A94D-4784-B178-BDB8F953F66DQ41556479-2DDF7C2E-BB41-4787-84A4-A3D8826FFC37Q41994735-494D5C3D-C565-4C52-AE08-A153ADCDBCF7Q42813123-B4E963AB-8D42-4594-9F55-A6C24ABB21ED
P2860
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Antiepileptic drugs increase p ...... vement of cytochrome p450 3A4.
@en
type
label
Antiepileptic drugs increase p ...... vement of cytochrome p450 3A4.
@en
prefLabel
Antiepileptic drugs increase p ...... vement of cytochrome p450 3A4.
@en
P2093
P2860
P356
P1476
Antiepileptic drugs increase p ...... lvement of cytochrome p450 3A4
@en
P2093
P2860
P304
38685-38689
P356
10.1074/JBC.M105127200
P407
P577
2001-08-20T00:00:00Z